Letter

Anticoagulation may be beneficial in high risk factor V Leiden carriers

BMJ 1998; 317 doi: 10.1136/bmj.317.7155.416 (Published 8 August 1998)
Cite this as: BMJ 1998;317:416

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Trevor Baglin, Consultant haematologist,
  2. Caroline Baglin, Clinical nurse specialist,
  3. Karen Brown, Senior technologist,
  4. Roger Luddington, Chief technologist,
  5. East Anglian Thrombophilia Study Group
  1. Clinical Haematology, Box 234, Addenbrooke's NHS Trust, Cambridge CB2 2QQ

    EDITOR—Sarasin and Bounameaux's decision analysis model of treatment in factor V Leiden carriers1 is in keeping with the results of our cohort study.2 In our study the annual rate of recurrence when treatment with warfarin was stopped was 11.1 per 100 patient-years. Patients who had an idiopathic first event were more likely to have a recurrence than those whose first event was precipitated (log rank=4.76, P=0.029). The recurrence …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular